4//SEC Filing
Virgin Herbert 4
Accession 0001209191-22-012952
CIK 0001706431other
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 9:30 PM ET
Size
12.7 KB
Accession
0001209191-22-012952
Insider Transaction Report
Form 4
Virgin Herbert
EVP, Research & CSO
Transactions
- Award
Common Stock
2022-02-22+70,000→ 175,407 total - Exercise/Conversion
Common Stock
2022-02-22$1.53/sh+1,375$2,104→ 176,782 total - Sale
Common Stock
2022-02-22$30.00/sh−1,375$41,250→ 175,407 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-02-22−1,375→ 219,505 totalExercise: $1.53Exp: 2028-01-26→ Common Stock (1,375 underlying) - Award
Stock Option (Right to Buy)
2022-02-22+70,000→ 70,000 totalExercise: $29.48Exp: 2032-02-21→ Common Stock (70,000 underlying)
Footnotes (4)
- [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
- [F3]The option is fully vested and exercisable.
- [F4]25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.
Documents
Issuer
Vir Biotechnology, Inc.
CIK 0001706431
Entity typeother
Related Parties
1- filerCIK 0001786378
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 9:30 PM ET
- Size
- 12.7 KB